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ABSTRACT 
The vancomycin dose for hemodialysis (HD) patients should be adjusted by monitoring drug serum 
concentrations. However, this procedure is not available in most health services in Brazil, which 
usually adopts protocols based on published studies. The trials available are controversial, and sev-
eral have not been conducted with current dialyzers. This study aimed at assessing the suitability of 
vancomycin serum concentrations in HD patients at a public hospital. Blood samples of HD patients 
were collected from November 2006 to May 2007, at time intervals of 48, 96, 120, or 168 hours after 
vancomycin administration. Drug measurement was performed with polarized light immunoﬂ uo-
rescence. Approximately 86% of trough vancomycin serum concentrations were below the recom-
mended value, indicating exposure to subtherapeutic doses and a higher risk for selecting resistant 
microorganisms.
Keywords: vancomycin, chronic renal failure, hemodialysis.
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INTRODUCTION
Vancomycin, an amphoteric and high-molec-
ular-weight complex tricyclic glycopeptide an-
tibiotic, available in the form of water-soluble 
hydrochloride, is often used for treating severe 
hospital infections.1 Vancomycin concomitant-
ly inhibits the cell wall synthesis of susceptible 
microorganisms or bacteria, altering cytoplasm 
membrane permeability and interfering with 
RNA synthesis.2 Its most signifi cant adverse ef-
fects are ototoxicity and nephrotoxicity. Marinho 
(2005) has reported that approximately 30% of 
patients have experienced some adverse reac-
tion to vancomycin, such as renal failure (18%), 
thrombocytopenia (7%), neutropenia (2%), red 
man syndrome (2%), and ototoxicity (1%).3
The increased use of vancomycin has been 
attributed to the increase of nosocomial infec-
tions caused by methicillin-resistant Staphylo-
coccus aureus (MRSA), which increased from 
2% in 1974 to more than 50% in 2000.4
Bacterial infections most often occur in he-
modialysis (HD) patients. This is most prob-
ably related to frequent violation of normal 
skin and mucosa barriers than to immune 
dysfunction. Bacterial infections in HD pa-
tients progress more rapidly and resolve less 
promptly than those in non-uremic patients.5 
Venous access site is the source of 50% to 80% 
of the bacteremia episodes in dialysis patients. 
Bacteremia can lead to endocarditis, meningi-
tis, osteomyelitis, paraspinal abscess, or forma-
tion of septic embolus. Arteriovenous fi stulas 
do not have an exit site, thus being associated 
with lower infection rates.6
In HD patients, infections caused by Gram-
positive bacteria can be treated with vanco-
mycin, mainly due to its activity against most 
Gram-positive pathogens, especially MRSA. 
Moreover, vancomycin has a long half life in 
renal failure, which allows using intermittent 
doses regimes.7 However, the pharmacokinetic 
characteristics of this antibiotic should be re-
spected to maintain adequate levels, minimize 
the appearance of resistant strains, and avoid 
toxicity.8 Changes in renal function associated 
with normal aging or with diseases can have a 
deep effect on the pharmacology of antibiotics, 
which require their doses to be adjusted.9,10,11 
The amount of vancomycin removed by 
HD is negligible when conventional dialyzers 
are used; however, when using high-ﬂ ow mem-
brane dialyzers, a signifi cant reduction in van-
comycin levels can occur.5,11
Measurement of vancomycin serum levels 
in patients with renal failure is required to as-
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sure adequate bactericidal levels. According to Lentino and 
Leehey (2001), vancomycin maximum and minimum serum 
levels are 30-40 µg/mL and 5-10 µg/mL, respectively.5
Due to the high variability of the minimum inhibi-
tory concentrations (MIC) for vancomycin-susceptible 
staphylococcus strains, a recent study has recommended 
that vancomycin levels range from 5 to 10 times the MIC 
value.12 
The suggested dose of vancomycin for HD patients is 
15 mg/kg every 7 to 10 days.13 However, when high-flow 
membranes are used in HD, additional vancomycin doses 
are recommended at every HD session.14 Lentino and Lee-
hey (2001) have recommended that the interval between 
vancomycin doses in HD patients should be enlarged, but 
treatment should begin with an attack dose of 20 mg/kg 
and continued with subsequent doses of 15 mg/kg every 
seven days after the HD session.5
Other authors have suggested changes in dosing and 
interval according to the administration regimen and the 
type of dialyzer used. However, reviewing studies on the 
pharmacokinetics of vancomycin in HD patients showed 
several limitations, different conclusions and suggestions 
of dose adjustment could be identified as shown in Table 
1. The divergences and limitations of the studies pub-
lished have motivated the conduction of this study that 
aimed at monitoring the serum levels of vancomycin in 
HD patients and checking if the concentrations were ad-
equate.
METHOD
The study was approved by the Research Ethics Committee 
of the Universidade de Sorocaba (Protocol 001/05) and by 
the Teaching and Research Committee of the Conjunto Hos-
pitalar de Sorocaba (state of São Paulo), a state public hospi-
tal that attends approximately 120 HD patients. All patients 
included in this study used vancomycin during the period 
studied (from November 2006 to May 2007) and provided 
written informed consent. The exclusion criteria were as fol-
lows: report of allergy to vancomycin, liver disease, or previ-
ous use of vancomycin up to 15 days before sample collec-
tion.
Data collection from medical records included the fol-
lowing: gender, age, origin, and ethnicity. The results of 
culture and antibiogram were obtained from the Hospital 
Infection Control Service of the Conjunto Hospitalar de So-
rocaba. 
Vancomycin (Vancocina CP – ABL Antibióticos do Bra-
sil) was given in dose of 1 g diluted into 100 mL of 0.9% so-
dium chloride solution infused during the last hour of HD, 
according to the service’s protocol, which recommends the 
administration of 1 g every seven days. Blood samples were 
collected by the nurse team in tubes containing ethylene 
diamine tetraacetic acid (EDTA) for hemogram and in dry 
tubes for measuring vancomycin and albumin. Then, they 
were centrifuged and frozen. The collections for measur-
ing vancomycin were obtained in single samples at the time 
points 48, 96, 120 or 168 hours after administering the fi rst 
dose of the drug.
Hemogram was performed in the automated ABX Pen-
tra60® device, at the Instituto Diagnóstico de Sorocaba. 
The endpoint colorimetric method was used for measuring 
albumin with a kit containing bromocresol green (BCG) 
of Laborlab, at the Universidade de Sorocaba. Vancomy-
cin serum levels were measured by using 150 µL of serum 
and polarized light immunoﬂ uorescence with monoclonal 
antibodies (ABBOTT Laboratories kits) in the automated 
AxSym® device (ABBOTT), in the sector of serology of the 
Hemonúcleo of the Conjunto Hospitalar de Sorocaba.
The results were reported regarding the percentage of 
patients with inadequate serum concentrations and need 
for dose adjustment. Statistical analyses (ANOVA) were per-
formed in the correlation of the results of vancomycin and 
albumin concentrations and hematocrit levels. The signifi -
cance level of 5% was adopted.
RESULTS
The study comprised 17 patients, fi ve of whom used van-
comycin more than once during the period studied, at a 
mean interval of 72 days, adding up to the collection of 22 
samples. Their mean age was 56.9 ± 6.0 years. Most patients 
(56%) were female, married (65%), white (65%), and came 
from the municipalities of the Sorocaba region (59%). 
The following clinical conditions related to HD proce-
dure stand out: double-lumen catheter as the most common 
venous access (65%); dialysis capillary reuse time ranging 
from 1-19 days, median of three days; association of diabe-
tes mellitus and arterial hypertension as the most frequent 
etiology of chronic renal failure (41%); mean HD time of 16 
months. All patients used polysulfone dialyzer membrane.
Patients’ laboratory data presented in Table 2 showed 
that albumin (reference values: 3.4-4.8 g/dL)21 and hemat-
ocrit (reference values: women: 39-49% and men: 35-45%)21 
were below normal values, but compatible with the setting 
of chronic renal failure. Neither statistical difference be-
tween groups (ANOVA), nor correlation between the pa-
tient’s plasma level of albumin and serum concentration of 
vancomycin were observed (p > 0.05). 
Regarding to vancomycin serum concentrations , no 
statistical difference (ANOVA, p > 0.05) between the val-
ues of the four groups was observed (Table 2). However, at 
least 14% of the results were inadequate when considering 
the minimum trough concentration greater than 5 µg/mL, 
and 86% were inadequate when considering the minimum 
trough concentration greater than 10 µg/mL (Figure 1). 
Staphylococci were identifi ed in one third of the cases, 
and approximately 25% of the microorganisms isolated 
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Table 1. Limitations, objectives and conclusions of the major studies on monitoring vancomycin in hemodialysis.
 Reference  Limitations of the study Goal Major conclusions
  Number of patients (four)  To check the renal excretion For anuric patients, 7% of
 Nielsen et al.  undergoing hemodialysis rate in several degrees of  the usual maintenance dose
 (1975)15 with no infection renal failure per unit of time are 
    recommended 
  They do not specify  To assess toxicity and Large variation in peak and
 Masur et al. the dialyzer used pharmacokinetics trough concentration (to
 (1982)16  in prolonged treatment  monitor). Negative cultures in
   (accumulation) the initial 48 hours of therapy.  
    Low toxicity
  Small number of patients  To correlate renal function For patients with creatinine
 Gonzáles-Martin with infection, several topographies  and vancomycin clearance < 10 mL/min-1,
 et al. (1996)17 and unstable patients (sepsis).  concentration vancomycin doses of 1 g every
  They also report peak concentration   seven days are suitable
  above the limit of toxicity
 Zoer; Schrander-  To check vancomycin Vancomycin clearance does not
 Van der Meer;   clearance with two types depend on HD flow.
 Van Dorp  Patients with no infection of dialyzers Recommendation: one gram  
 (1997)18   initially + 500 mg during each  
    subsequent HD session
     To assess the pharmacokinetics   25 mg/kg during HD 
   of high doses of vancomycin  determine adequate  
 Foote et al. Five patients in F80-Fresenius polysulfone  concentration for up to
 (1998)19 with no infection membrane  seven days and subsequent
    doses should be adjusted  
    according to serum 
    concentration
    To determine the amount of  Vancomycin administered
 Lucksiri et al.  vancomycin removed by the during the last hour of HD
 (2002)20 Patients with no infection CAHP-210 dialyzer results in a 24%-lower  
    concentration than when 
    administered after HD
    To compare three regimens  Administration of 30 mg/kg
 Mason et al. Patients with no infection of vancomycin dosing during HD is equivalent to  
 (2003)7   administration of 15 mg/kg  
    after HD
Figure 1: Graphic representation of vancomycin measurement results in samples of patients with renal failure undergoing 
hemodialysis (n = 22). MRC = minimum recommended concentration.
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were Staphylococcus aureus. Of those, 50% were oxacillin-
resistant, and 100% were sensitive to vancomycin.
DISCUSSION
Several studies used for establishing the current empirical 
protocols of vancomycin dosing in patients with renal failure 
undergoing HD are outdated with regards to dialysis equip-
ments. The manufacturer of the reference drug (Vancocin®) 
reports that it is not dialyzable and its half life is 7.5 days in 
patients with severe renal failure. However, the various tri-
als have different case series and several limitations, such as 
the small number of patients, unstable patients (with sepsis), 
patients with no infection, and patients using different types 
of dialyzers. Launay-Vaucher et al. (2002) have discussed the 
use of several dialysis membranes and systems aiming at es-
tablishing protocols for monitoring serum concentration. In 
fact, that aspect has been seldom explored in the international 
literature, since most hospitals in developed countries moni-
tor vancomycin concentration in patients at risk (neonates, 
patients with large burns, patients with renal failure, and the 
elderly). In Brazil, however, few hospitals do this on a regular 
basis. The cost of that automated test is considered a limiting 
factor and is equivalent to the mean price of one drug vial.10
Currently, approximately 80% of the hospital sta-
phylococcal infections are treated with glycopeptides, 
such as vancomycin and teicoplanin. This is still the an-
timicrobial class of choice for treating infections caused 
by MRSA, although strains with reduced sensitivity to 
vancomycin have already been isolated in Brazil.22
The accessory gene regulator (agr) of Staphylococcus 
aureus modulates the expression of numerous virulence 
factors in the phase-dependent growth. According to 
Rose et al. (2007), all agr groups develop intermediate 
resistance to vancomycin with subtherapeutic expo-
sures.23
The study by Sakoulas et al. (2006) has shown that 
the exposure to subtherapeutic vancomycin concentra-
tions is associated with the development of clinically 
hetero-GISA (glycopeptide intermediate-resistant S. au-
reus) isolates. These authors consider that the constant 
Table 2. Laboratory data and vancomycin measurement in samples (n = 22) of HD patients
 Groups Samples Patient Hematocrit Total leukocytes  Albumin (g/dL) Vancomycin
     (%) (10³/mm³)  (µg/mL)
  1 A NI NI 2.67 7.80 
 Group 1 2 B NI NI 2.24 8.17 
 48h 3 C NI NI 2.46 8.64 
 n = 7 4 D* 26.10 5.70 2.35 8.94
  5 E 20.40 6.90 2.78 7.44
  6 F* 24.10 15.80 1.92 7.03
  7 G 17.00 2.40 2.56 10.92
 Mean ± SD   21.90 ± 4.00 7.70 ± 5.70 2.40 ± 0.30 8.40 ± 1.30
 Group 2 8 H 22.20 16.80 NI 9.68
 96h 9 I* 22.00 7.90 2.88 5.25
 n = 4 10 J* NI NI 2.35 11.54
  11 G 16.10 4.20 2.88 8.35
 Mean ± SD   20.10 ± 3.50 9.60 ± 6.80 2.70 ± 0.30 8.70 ± 2.60
 Group 3 12 C 27.10 6.90 3.20 3.13
 120h 13 K 29.80 4.80 3.20 5.14
 n = 4 14 L 24.60 4.70 2.88 5.23
  15 A 24.80 2.80 3.20 9.06
 Mean ± SD   26.60 ± 2.40 4.80 ± 1.70 3.10 ± 0.20 5.60 ± 2.50
  16 M* 32.20 6.40 3.31 1.86
  17 L 31.60 5.60 3.31 1.42
 Group 4 18 D 18.00 3.90 2.56 5.19
 168h 19 N 20.50 6.40 3.52 6.23
 n = 7 20 O 20.00 1.90 3.74 10.13
  21 P 24.30 10.40 2.78 5.56
  22 Q* NI NI 2.78 7.16
 Mean ± SD   24.40 ± 6.10 5.80 ± 2.80 3.10 ± 0.40 5.40 ± 3.00
*Patients with confirmed diagnosis of staphylococcal infection. 
SD = standard deviation; NI = no information
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exposure of microorganisms to a vancomycin concen-
tration >10 mg/L is important in preventing the appear-
ance of intermediate resistance to glycopeptides.24
Johnson and Woodford (2002), studying glycopeptide 
resistant S. aureus (GRSA), have reported that GRSA isolat-
ed in Michigan with one vanA gene, along with other genes, 
encode a high level of resistance to glycopeptides.25
Due to the increasing use of vancomycin, worrisome 
vancomycin-resistant strains of E. faecium and E. faecalis 
have emerged. The determinant of this resistance is located 
in a transposon that is part of a plasmid; thus, the vancomy-
cin-resistant enterococcus can transfer its resistance to other 
Gram-positive bacteria, such as staphylococci, worsening 
even more the occurrence of multi-resistant bacteria.3
The GISA and GRSA resistances, although still rare, should 
be under constant multidisciplinary surveillance. The follow-
ing patients are at risk for GISA: patients receiving prolonged 
vancomycin therapy; patients previously colonized by MRSA 
or vancomycin-resistant enterococci (VRE), particularly those 
with peritoneal catheters; patients with documented MRSA 
infection; and HD patients, who frequently have MRSA and 
undergo therapy with glycopeptides.26
Because VRE are usually resistant to other antibiotics 
commonly used in hospitals, severe exposure to other drugs 
is associated with a high risk of acquiring VRE.27
Similarly to beta-lactam antibiotics, vancomycin has 
negligible post-antibiotic effects and requires the mainte-
nance of concentrations equivalent to four to fi ve times MIC 
during prolonged periods to obtain an effi cient antibacterial 
effect.8
In clinical practice in Brazilian hospitals, dosing for most 
patients with chronic renal failure is 1 g every seven days. 
However, in a study by González-Martin et al. (1996), the 
vancomycin level seven days after administration was low-
er than expected and a subtherapeutic level was probably 
achieved days before.17 
Zoer et al. (1997) have recommended an initial vanco-
mycin dose of 1 g, to which 500 mg should be added dur-
ing each subsequent HD session in patients with a positive 
culture for S. aureus. The ideal time for plasma monitoring 
would occur 48h, and 96h or 120h after vancomycin infu-
sion.18 Other authors have recommended the determination 
of vancomycin serum concentration before the fi rst HD ses-
sion subsequent to the administration and before 72-hour 
of HD session. If the results are below the recommended 
values (between 5 and 10 µg/mL), a complementary 500-mg 
dose of vancomycin can be used.5,28
It is worth noting that, in this study, 86% of the pa-
tients had concentrations below 10 µg/mL and 14% of the 
patients had concentrations below 5 µg/mL. When the col-
lection times are considered, one can infer that the number 
of patients reaching trough concentrations below 5 µg/mL 
would be greater. It is also worth noting that vancomycin 
has been administered during the HD session, but supple-
mentary doses are not administered according to the recom-
mendation of Mason et al. (2003) who have compared three 
regimens of vancomycin dosing.7
In conclusion, the patients included in this study were 
exposed to antibiotic subtherapeutic doses. Considering the 
increased risk of selecting resistant microorganisms, moni-
toring of vancomycin serum concentration in HD patients 
is recommended. 
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